MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Cambridge Biomedical Centre, Cambridge, UK.
Osteoporos Int. 2017 Dec;28(12):3495-3500. doi: 10.1007/s00198-017-4200-3. Epub 2017 Aug 31.
In this study, we report that self-perception of fracture risk captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is associated with improved medication uptake. It suggests that adequate appreciation of fracture risk may be beneficial and lead to greater healthcare engagement and treatment.
This study aimed to assess how well self-perception of fracture risk, and fracture risk as estimated by the fracture prediction tool FRAX, related to fracture incidence and uptake and persistence of anti-osteoporosis medication among women participating in the Global Longitudinal study of Osteoporosis in Women (GLOW).
GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America and Australia. Aged ≥ 55 years, 60,393 women completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk (SPR). Annual follow-up included self-reported incident fractures and anti-osteoporosis medication (AOM) use. We calculated FRAX risk without bone mineral density measurement.
Of the 39,241 women with at least 1 year of follow-up data, 2132 (5.4%) sustained an incident major osteoporotic fracture over 5 years of follow-up. Within each SPR category, risk of fracture increased as the FRAX categorisation of risk increased. In GLOW, only 11% of women with a lower baseline SPR were taking AOM at baseline, compared with 46% of women with a higher SPR. AOM use tended to increase in the years after a reported fracture. However, women with a lower SPR who were fractured still reported lower AOM rates than women with or without a fracture but had a higher SPR.
These results suggest that SPR captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is also associated with improved medication uptake.
本研究旨在评估自我感知的骨折风险以及骨折预测工具 FRAX 估计的骨折风险与骨折发生率、抗骨质疏松药物的使用及持续情况之间的关系,这些数据来自参与全球女性骨质疏松纵向研究(GLOW)的女性。
GLOW 是一项国际队列研究,涉及欧洲、北美和澳大利亚 10 个国家的 723 个医生诊所。年龄≥55 岁的 60393 名女性完成了基线调查问卷,详细记录了病史,包括合并症、骨折和自我感知的骨折风险(SPR)。年度随访包括自我报告的新发骨折和抗骨质疏松药物(AOM)使用情况。我们计算了不基于骨密度测量的 FRAX 风险。
在至少有 1 年随访数据的 39241 名女性中,5 年内有 2132 名(5.4%)发生了主要骨质疏松性骨折。在每个 SPR 类别中,随着 FRAX 风险分类的增加,骨折风险增加。在 GLOW 中,基线 SPR 较低的女性中,只有 11%在基线时服用 AOM,而基线 SPR 较高的女性中,这一比例为 46%。在报告骨折后的几年中,AOM 的使用呈上升趋势。然而,SPR 较低且骨折的女性报告的 AOM 率仍低于无骨折或 SPR 较高的女性。
这些结果表明,SPR 捕捉到了目前使用常规骨折预测工具无法测量的某些骨折风险,并与改善药物使用有关。